Comparing Inclisiran Versus Statin for Primary Aldosteronism
A Randomized Controlled Study Comparing Inclisiran Plus Spironolactone Versus Statin Plus Spironolactone for Primary Aldosteronism
Primary aldosteronism represents one of the leading causes of resistant hypertension. Circulating cholesterol is established as the exclusive substrate for adrenal aldosterone synthesis, and statins, which suppress cholesterol production, are currently widely applied in clinical settings. Emerging clinical evidence has demonstrated that in patients with essential hypertension, the plasma aldosterone level decreased by 43% (from 13.9 ng/dL to 7.9 ng/dL) after treatment with PCSK9 inhibitors. However, the effect of PCSK9 inhibitors with superior lipid-lowering efficacy combined with amlodipine besylate on aldosterone levels remains elusive. The present clinical trial adopted inclisiran, a PCSK9 inhibitor with well-documented clinical safety and robust lipid-lowering effects, in combination with amlodipine besylate. Through randomized grouping intervention and follow-up, this study aimed to compare the differential effects of two therapeutic regimens-inclisiran-based therapy and statin-based therapy-on plasma aldosterone levels, as well as improvements in a spectrum of clinical parameters including blood pressure , serum potassium and so on in patients with primary aldosteronism. The outcomes of this trial are expected to provide novel and more effective pharmacological strategies for the management of primary aldosteronism.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Liyuan Yuan
- Numéro de téléphone: +8617374960635
- E-mail: 706539967@qq.com
Sauvegarde des contacts de l'étude
- Nom: Zhiming Zhu
Lieux d'étude
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Chine, 400042
- Recrutement
- Daping Hospital,Third Military Medical University
-
Contact:
- Zhiming Zhu
- Numéro de téléphone: +8613608313322
- E-mail: hbpcms@sina.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with hypertension aged18-70years.
- Meeting the diagnostic criteria for primary aldosteronism (PA) according to the *Expert Consensus on the Diagnosis and Treatment of Primary Aldosteronism (2025 Edition)
- Patients either untreated or on antihypertensive therapy; after a 1-2week washout period, blood pressure is <160/100mmHg.
- Serum potassium at the end of the run-in period: 3mmol/L ≤ serum potassium <5mmol/L.
- Voluntary participation in the trial and provision of written informed consent.
Exclusion Criteria:
- Office blood pressure >180/110mmHg.
- Severe hepatic insufficiency or severe renal insufficiency.
- Acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, or cerebrovascular accident within the previous 6 months; heart failure of NYHA class II-IV.
- Serum potassium <2.5mmol/L or >5.5mmol/L.
- Pregnancy or planned pregnancy within 1year.
- Neurological or psychiatric disorders.
- Concurrent malignant neoplasm.
- Low-density-lipoprotein-cholesterol(LDL-C) <2.6mmol/L.
- Any other conditions that, in the investigator's opinion, may interfere with efficacy and/or safety assessment of the study (including but not limited to poor subject compliance or inability to attend scheduled follow-up due to long-distance residence).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Subcutaneous inclisiran plus oral amlodipine besylate and spironolactone
Participants receive inclisiran 284 mg subcutaneously (initial dose, repeat at 3 months) plus oral amlodipine besylate 5 mg once daily and oral spironolactone 20 mg once daily. |
Subcutaneous inclisiran oral Spironolactone oral Amlodipine besylate |
|
Comparateur placebo: Statin plus amlodipine besylate and spironolactone
Participants receive oral simvastatin 40 mg, oral amlodipine besylate 5 mg once daily, and oral spironolactone 20 mg once daily. |
oral Spironolactone oral Amlodipine besylate oral Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Change from baseline in plasma aldosterone level
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change from baseline in systolic and diastolic blood pressure
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
|
Change from baseline in plasma renin concentration
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
|
Change from baseline in 24-hour urinary aldosterone
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
|
Change from baseline in serum potassium level
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
|
Change from baseline in plasma lipid
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
|
Change from baseline in glucose
Délai: 24 weeks after randomization
|
24 weeks after randomization
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vohringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;132(19):1825-33. doi: 10.1161/CIRCULATIONAHA.115.016759. Epub 2015 Oct 2.
- Wu H, He H, Han T, Tian X, Zhu Z. Targeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism. Trends Endocrinol Metab. 2025 Sep;36(9):789-801. doi: 10.1016/j.tem.2024.12.001. Epub 2025 Jan 6.
- Izkhakov E, Shacham Y, Serebro M, Yaish I, Marcus Y, Shefer G, Tordjman K, Greenman Y, Stern N, Ziv-Baran T. The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study. J Clin Med. 2021 Jun 5;10(11):2504. doi: 10.3390/jcm10112504.
- Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):40-51. doi: 10.7326/M14-2957.
- Capponi AM. Regulation of cholesterol supply for mineralocorticoid biosynthesis. Trends Endocrinol Metab. 2002 Apr;13(3):118-21. doi: 10.1016/s1043-2760(01)00538-0.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies des glandes surrénales
- Hyperfonction corticosurrénalienne
- Hyperaldostéronisme
- Produits chimiques organiques
- Pyridines
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Acides gras
- Lipides
- Azoles
- Hydrocarbures
- Hydrocarbures, cyclique
- Naphtalenes
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Indoles
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Lactones
- Pyrroles
- Acides heptanoïques
- Présceau
- Dihydropyridines
- Atorvastatine
- Spironolactone
- Amlodipine
- Simvastatine
- Lovastatine
- Préparations pharmaceutiques
- pitavastatine
- ALN-PCS
- Fluvastatine
Autres numéros d'identification d'étude
- ISPA
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .